Dalbavancin: A Viewpoint by Eric S. Schweiger

By Schweiger Eric S.  

Drugs, Vol. 68, Iss. 5, 2008-01 ,pp. : 649-651

Adis International

Access to resources Recommend Favorite

New Lipoglycopeptides: A Comparative Review of Dalbavancin, Oritavancin and Telavancin

By Zhanel George G.   Calic Divna   Schweizer Frank   Zelenitsky Sheryl   Adam Heather   Lagacé-Wiens Philippe R.S.   Rubinstein Ethan   Gin Alfred S.   Hoban Daryl J.   Karlowsky James A.  

Drugs, Vol. 70, Iss. 7, 2010-05 ,pp. : 859-886

Adis International

Access to resources Recommend Favorite

Dalbavancin equivalent to linezolid, cefazolin, vancomycin for SSTI

By  

Inpharma, Vol. 1, Iss. 1451, 2004-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Two-dose dalbavancin effective in skin and soft tissue infections

By  

Inpharma, Vol. 1, Iss. 1414, 2003-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide

By Jones R.N.   Streit J.M.   Fritsche T.R.  

International Journal of Antimicrobial Agents, Vol. 23, Iss. 2, 2004-02 ,pp. : 197-199

Elsevier

Access to resources Recommend Favorite